TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27464553

Group type: EXPERIMENTAL
Intervention: IR1 sign (temperature of cancer site minus that of the contralateral mirror imaging site)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: IR1 sign
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: IR1 and IR5 (asymmetrical thermographic pattern)
Number of subjects: 143
Study: 27464588

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 2570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2570
Study: 27464708

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR) with clipping for deep mural injury (DMI)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Type III-V DMI
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Type I/II DMI
Number of subjects: 802
Study: 27464822

Group type: EXPERIMENTAL
Intervention: CTC negative patients
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CTC negative patients (G2 grading)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CTC negative patients with no lymph node metastasis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: sFlt1 and PlGF
Number of subjects: 200
Study: 27464938

Group type: EXPERIMENTAL
Intervention: Lentivirus-mediated shRNA targeting GHSR1a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blank control (BC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scrambled control (SC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GHSR1a knockdown in vivo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blank control tumors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control tumors
Number of subjects: 0
Study: 27465021

Group type: EXPERIMENTAL
Intervention: Ganglioneuroma (GN)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Ganglioneuroblastoma intermixed (GNBI)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Residual tumors (42 GN, 13 GNBI)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Subtotal resection
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Ganglioneuroma (GN) and Ganglioneuroblastoma intermixed (GNBI)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 217
Study: 27465105

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 21
Study: 27465382

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D concentrations
Number of subjects: 100
Study: 27465398

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (no MVPA)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Overall weight, BMI, fat mass, and subcutaneous adiposity
Number of subjects: 59
Study: 27465647

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (4 mg/kg) administered prior to MRI
Number of subjects: 20
Study: 27466046

Group type: EXPERIMENTAL
Intervention: Scheduled SMS text message reminder for MV
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Voice call plus SMS text message reminder for MV
Number of subjects: 990

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: All groups (Intervention and Control)
Number of subjects: 990
Study: 27466061

Group type: EXPERIMENTAL
Intervention: Newly-developed, higher-concentration formulation of a dual-acting antihistamine-mast cell stabilizer, once-daily dosing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-acting antihistamine-mast cell stabilizing agents (first-line therapeutics for AC).
Number of subjects: 0
Study: 27466073

Group type: EXPERIMENTAL
Intervention: Sealant recommendation for a 12-year-old patient with high caries risk in three hypothetical scenarios.
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Dentist agreement with the efficacy of assessment for caries risk.
Number of subjects: 282
Study: 27466607

Group type: EXPERIMENTAL
Intervention: Low serum zonulin group (<46.4 ng/mL)
Number of subjects: 100
Study: 27467111

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) monitoring of abdominal oxygenation (ArSO2) at first enteral feed
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Splanchnic-cerebral oxygenation ratio calculation
Number of subjects: 61
Study: 27467121

Group type: EXPERIMENTAL
Intervention: Sonidegib 400 mg q.d.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sonidegib 600 mg q.d.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sonidegib 800 mg q.d.
Number of subjects: 45
Study: 27467683

Group type: EXPERIMENTAL
Intervention: Microcrystalline zinc hydroxyapatite (mHA) dentifrice, n = 33
Number of subjects: 70

Group type: COMPARATOR
Intervention: AmF/SnF2 dentifrice, n = 34
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both mHA and AmF/SnF2 dentifrices
Number of subjects: 70
Study: 27467907

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Risk score for atrial fibrillation occurrence
Number of subjects: 1782
Study: 27468653

Group type: EXPERIMENTAL
Intervention: Mobile ACT intervention (8-week duration)
Number of subjects: 74
Study: 27468937

Group type: EXPERIMENTAL
Intervention: Urine testing for EGFR mutations
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Plasma testing for EGFR mutations
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combined urine and plasma testing
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Monitoring urine T790M levels in patients receiving rociletinib
Number of subjects: 63
Study: 27468938

Group type: EXPERIMENTAL
Intervention: ctDNA from plasma for EGFR mutation testing
Number of subjects: 1288

Group type: COMPARATOR
Intervention: Tissue/cytologic samples for EGFR mutation testing
Number of subjects: 1288
Study: 27470087

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine A (CyA) 2 mg/kg body weight per day for 16 weeks
Number of subjects: 30
Study: 27470600

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 130
Study: 27470602

Group type: EXPERIMENTAL
Intervention: Abnormal remission karyotypes
Number of subjects: 258

Group type: COMPARATOR
Intervention: Normal remission karyotypes
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Any clonal or non-clonal chromosome abnormality at complete remission
Number of subjects: 258

Group type: COMPARATOR
Intervention: Exclusively normal metaphases
Number of subjects: 258
Study: 27471042

Group type: EXPERIMENTAL
Intervention: Low SES families (census tracts with ≥15% living in poverty)
Number of subjects: 61

Group type: COMPARATOR
Intervention: High SES families (census tracts with <15% living in poverty)
Number of subjects: 61
Study: 27471224

Group type: EXPERIMENTAL
Intervention: EHR identified individuals in need of CRC screening (520 individuals)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: EHR flagged individuals as up-to-date in their screening (280 individuals)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Patients incorrectly classified as eligible (61 individuals)
Number of subjects: 800
Study: 27471593

Group type: EXPERIMENTAL
Intervention: Tap water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lemonade (90 g/L carbohydrates)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isotonic saline (9 g/L)
Number of subjects: 10
Study: 27471619

Group type: EXPERIMENTAL
Intervention: Anti-Gram-positive antibiotics in CLL patients (n = 45/800)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Anti-Gram-positive antibiotics in relapsed lymphoma patients (n = 21/122)
Number of subjects: 922
Study: 27472034

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Chemotherapy with or without radiotherapy (C/R)
Number of subjects: 102
Study: 27472156

Group type: EXPERIMENTAL
Intervention: Bevacizumab-based chemotherapy with baseline CD138 measurement
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Biological prognostic score including CD138 and LDH values
Number of subjects: 177
Study: 27473031

Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa treatment
Number of subjects: 16
Study: 27473040

Group type: EXPERIMENTAL
Intervention: Experiences of violence from school staff
Number of subjects: 3565

Group type: EXPERIMENTAL
Intervention: Experiences of violence from other students
Number of subjects: 3565

Group type: EXPERIMENTAL
Intervention: Low school connectedness
Number of subjects: 3565

Group type: EXPERIMENTAL
Intervention: Never feeling close to other students at school
Number of subjects: 3565

Group type: EXPERIMENTAL
Intervention: Attending an urban school
Number of subjects: 3565
Study: 27473119

Group type: EXPERIMENTAL
Intervention: Systematic ICU admission (intervention group)
Number of subjects: 3036

Group type: COMPARATOR
Intervention: Standard practices regarding ICU admission (control group)
Number of subjects: 3036
Study: 27473350

Group type: EXPERIMENTAL
Intervention: ACTH infusion
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: hCG injection
Number of subjects: 28
Study: 27473473

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study: 27473569

Group type: EXPERIMENTAL
Intervention: Depression Education Intervention (DEI)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Self-report depression screening tool (PHQ-9) via customized web application
Number of subjects: 350
Study: 27473726

Group type: EXPERIMENTAL
Intervention: Reduction or total elimination of animal protein from the diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard oncological therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online study platform
Number of subjects: 0
Study: 27473815

Group type: EXPERIMENTAL
Intervention: Temozolomide and capecitabine-based preoperative chemoradiation therapy (CRT)
Number of subjects: 22
Study: 27473949

Group type: EXPERIMENTAL
Intervention: MDR bacteria
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Other pathogens
Number of subjects: 1000
Study: 27474016

Group type: EXPERIMENTAL
Intervention: Linear growth (measured by length-for-age z score)
Number of subjects: 3700

Group type: COMPARATOR
Intervention: Developmental stimulation or maternal supplementation
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Growth faltering
Number of subjects: 3700
Study: 27474021

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D (full factorial randomization)
Number of subjects: 2573

Group type: EXPERIMENTAL
Intervention: Calcium with vitamin D (two-group randomization)
Number of subjects: 2573

Group type: EXPERIMENTAL
Intervention: Calcium alone (two-group randomization)
Number of subjects: 2573

Group type: COMPARATOR
Intervention: Placebo (during 3-month single-blinded run-in)
Number of subjects: 2573
Study: 27474385

Group type: EXPERIMENTAL
Intervention: Profile 2 (moderate risk)
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Profile 3 (high risk)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Profile 1 (low risk)
Number of subjects: 624
Study: 27474763

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg every 4 weeks for 4 months
Number of subjects: 20
Study: 27475428

Group type: EXPERIMENTAL
Intervention: TPCS2a (0.25 mg/kg, escalated to 0.5, 1.0, and 1.5 mg/kg) followed by bleomycin (15,000 IU/m²) and laser illumination (652 nm, 60 J/cm²)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: TPCS2a (1.0 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: TPCS2a (1.5 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: TPCS2a (0.25 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: TPCS2a (not specified)
Number of subjects: 22
Study: 27475524

Group type: EXPERIMENTAL
Intervention: Low MIP (MIP ≤30 cmH2O)
Number of subjects: 124

Group type: COMPARATOR
Intervention: High MIP (MIP >30 cmH2O)
Number of subjects: 124
Study: 27475526

Group type: EXPERIMENTAL
Intervention: Intact embryos with mitosis resumption after overnight culture
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Embryos with 8 cells after warming or >9 cells after overnight culture
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Embryos with <6 cells after warming or ≤6 cells after overnight culture
Number of subjects: 986

Group type: COMPARATOR
Intervention: Embryos with fragmentation >10% and/or symmetry <75%
Number of subjects: 986
Study: 27475674

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) dose of 36 Gy with a 9-Gy simultaneous in-field boost (SIB) to the positive margins (PM), delivered in 3 fractions.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) dose escalation plan up to 45 Gy.
Number of subjects: 13
Study: 27475998

Group type: EXPERIMENTAL
Intervention: Multi-level pregnancy test (MLPT)
Number of subjects: 404
Study: 27476767

Group type: EXPERIMENTAL
Intervention: DHCE-MRI using Gd-EOB-DTPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-treatment ICG retention test (ICG R)
Number of subjects: 0
Study: 27476790

Group type: EXPERIMENTAL
Intervention: HCT-ASCT with rituximab 375 mg/m(2), carmustine 400 mg/m(2), thiotepa 2×5 mg/kg, and stem cell infusion
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Induction treatment with five courses of intravenous rituximab 375 mg/m(2) and four courses of intravenous high-dose methotrexate 8000 mg/m(2)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: HCT-ASCT
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 79
Study: 27476810

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam 4.5 g 2-3 times daily by intermittent infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Piperacillin trough level of 22.5 mg/L
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Total piperacillin trough levels threshold of 70 mg/L
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Total piperacillin target range ≥70 mg/L
Number of subjects: 60
Study: 27477483

Group type: EXPERIMENTAL
Intervention: GG genotype for SNP rs1800629 at the TNFA gene
Number of subjects: 840

Group type: COMPARATOR
Intervention: A-allele subjects
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: GG subjects for SNP rs1800629
Number of subjects: 840
Study: 27478115

Group type: EXPERIMENTAL
Intervention: 1-month triple antithrombotic therapy (TAT)
Number of subjects: 568

Group type: COMPARATOR
Intervention: >1-month triple antithrombotic therapy (TAT)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: 1-month TAT
Number of subjects: 568

Group type: COMPARATOR
Intervention: >1-month TAT
Number of subjects: 568
Study: 27478897

Group type: EXPERIMENTAL
Intervention: Infants with colic
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study: 27479107

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 178
Study: 27479177

Group type: EXPERIMENTAL
Intervention: NS-018 (300 mg once daily)
Number of subjects: 48
Study: 27479781

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 850000

Group type: COMPARATOR
Intervention: Other phosphate binders (concomitant therapy)
Number of subjects: 850000

Group type: COMPARATOR
Intervention: Historical control (before availability of lanthanum carbonate)
Number of subjects: 850000
Study: 27479814

Group type: EXPERIMENTAL
Intervention: High-resolution imaging (optical coherence tomography [OCT] and adaptive optics scanning light ophthalmoscopy [AOSLO])
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Peak cone density measurement
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Assessment of foveal outer nuclear layer thickness using OCT
Number of subjects: 51
Study: 27479825

Group type: EXPERIMENTAL
Intervention: International Myeloma Working Group score
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Revised Myeloma Comorbidity Index
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation-Comorbidity Index
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Kaplan-Feinstein Index
Number of subjects: 125
Study: 27480288

Group type: EXPERIMENTAL
Intervention: Magnetic-controlled capsule endoscopy (MCCE)
Number of subjects: 52
Study: 27480830

Group type: EXPERIMENTAL
Intervention: Dietary salicylate avoidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leukotriene-modifying drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desensitization with daily aspirin therapy
Number of subjects: 0
Study: 27480854

Group type: EXPERIMENTAL
Intervention: Daily therapy with 250 mg of AZM (n = 77)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Intermittent therapy with 500 mg of AZM three times weekly (n = 89)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Daily therapy with 250 mg of AZM for MABC-LD (n = 55)
Number of subjects: 221
Study: 27480993

Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 120
Study: 27481622

Group type: EXPERIMENTAL
Intervention: Leucocyte surface markers (biomarkers) assessed using flow cytometry in patients with suspected sepsis (n=300)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Leucocyte surface markers (biomarkers) assessed using flow cytometry in critically ill patients with established sepsis (n=100)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Leucocyte surface markers (biomarkers) assessed using flow cytometry in age and gender matched patients without suspicion of infection (n=100)
Number of subjects: 500
Study: 27482854

Group type: EXPERIMENTAL
Intervention: World Health Organization 5-Item Well-Being Index (WHO-5)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire (PHQ-9)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory II (BDI-II)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Montgomery-Åsberg Depression Rating Scale (MADRS)
Number of subjects: 262
Study: 27482888

Group type: EXPERIMENTAL
Intervention: CD19-specific CAR T cells generated using the Sleeping Beauty transposon system and AaPCs
Number of subjects: 26
Study: 27482964

Group type: EXPERIMENTAL
Intervention: Chronic symptomatic norovirus infection with diarrhea (noro group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Chronic diarrhea in the absence of norovirus (control group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison of noro group to control group
Number of subjects: 15
Study: 27483008

Group type: EXPERIMENTAL
Intervention: BD FACSPresto™ Near-Patient CD4 Counter
Number of subjects: 351
Study: 27483391

Group type: EXPERIMENTAL
Intervention: Pimasertib (60 mg oral dose)
Number of subjects: 6
Study: 27484458

Group type: EXPERIMENTAL
Intervention: Psychological intervention (suggestions before anesthesia)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (no suggestions before anesthesia)
Number of subjects: 270
Study: 27484756

Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 2258

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2258
Study: 27485208

Group type: EXPERIMENTAL
Intervention: Exogenous TRH administration
Number of subjects: 73
Study: 27485822

Group type: EXPERIMENTAL
Intervention: Gray Matters mobile phone app
Number of subjects: 144
Study: 27485934

Group type: EXPERIMENTAL
Intervention: Facebook-based peer group intervention for mothers with weekly video-based curriculum and optional face-to-face event.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Facebook-based peer group intervention for mothers.
Number of subjects: 8
Study: 27486034

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (400 mg/100 mg) plus GS-9857 (100 mg) once daily for 6-12 weeks
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (400 mg/100 mg) plus GS-9857 (100 mg) once daily for 6-12 weeks plus ribavirin
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (400 mg/100 mg) plus GS-9857 (100 mg) once daily for 12 weeks
Number of subjects: 197
Study: 27486033

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (400 mg/100 mg fixed-dose combination tablet) and GS-9857 (100 mg) once daily for 6-12 weeks
Number of subjects: 128
Study: 27486205

Group type: EXPERIMENTAL
Intervention: Individualized prediction model for forced expiratory volume at 1 second (FEV) derived from mixed-effects regression models.
Number of subjects: 5594
Study: 27486340

Group type: EXPERIMENTAL
Intervention: PEG 3350 ASC (17 g once daily for 14 days)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PEG 3350 ASC
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: COMPARATOR
Intervention: PEG 3350 ASC and Placebo
Number of subjects: 65
Study: 27486524

Group type: EXPERIMENTAL
Intervention: ETN 25 mg + MTX
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MTX
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ETN 50 mg + MTX (Phase I)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Phase II)
Number of subjects: 120
Study: 27486545

Group type: EXPERIMENTAL
Intervention: Adapted collaborative care intervention
Number of subjects: 67
Study: 27486629

Group type: EXPERIMENTAL
Intervention: Trastuzumab with Perioperative Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab without Pertuzumab
Number of subjects: 0
Study: 27486660

Group type: EXPERIMENTAL
Intervention: Intervention (school-based low-volume high-intensity interval training)
Number of subjects: 101
Study: 27486704

Group type: EXPERIMENTAL
Intervention: NL-1000 pedometer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Piezo pedometer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SC-T2 pedometer
Number of subjects: 60

Group type: COMPARATOR
Intervention: All pedometers
Number of subjects: 60
Study: 27486995

Group type: EXPERIMENTAL
Intervention: Metabolite index based on early umbilical cord blood alterations (succinate, glycerol, 3-hydroxybutyrate, O-phosphocholine)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard biochemical markers at birth
Number of subjects: 31

Group type: COMPARATOR
Intervention: EEG and Sarnat score
Number of subjects: 31
Study: 27487311

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ilioinguinal and iliohypogastric nerve block (ILI+IHG)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided posterior transversus abdominis plane block (TAP)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 149